Nifedipine in the Treatment of Hypertension in Systemic Lupus Erythematosus

Bursztyn, Michael; Many, Amira; Rosenthal, Talma
May 1987
Angiology;May1987, Vol. 38 Issue 5, p359
Academic Journal
Treatment of hypertension in systemic lupus erythematosus (SLE) may be complicated by unwanted immunologic vascular and renal side effects of drugs. The safety of long-acting nifedipine tablets was studied in 8 SLE hypertensive subjects for six months. Nifedipine reduced blood pressure from a mean 151.9 ±10/103.7 ± 8.6 mmHg to a mean of 130±14.1/87.5 ± 5 mmHg. There was no deterioration of renal function or of hematologic or immunologic indices during that period. We believe nifedipine is a safe and effective hypotensive drug in SLE, either alone or combined with beta blockers and diuretics.


Related Articles

  • CUTANEOUS REACTIONS DUE TO ANTIHYPERTENSIVE DRUGS. Upadhayai, J. B.; Nangia, Anup Kumar; Mukhija, R. D.; Misra, Mukum; Mohan, Lalit; Singh, K. K. // Indian Journal of Dermatology;2006, Vol. 51 Issue 3, p189 

    Out of a total of 1147 patients on antihypertensive drugs, 23 (2.04%) developed adverse cutaneous drug reactions (ACDR). The commonest antihypertensive drug group causing ACDR was beta-blockers of which atenolol was the commonest culprit. The second most common group was calcium channel blockers...

  • Adverse Reaction Case Reports.  // Reactions Weekly;10/16/2004, Issue 1023, p6 

    Presents case reports regarding the side effects of several drugs. Hepatitis in an elderly patient induced by alfuzosin; Poliomyositis during treatment with fluvastatin; Quadriparesis induced by bisoprolol treatment.

  • Nifedipine and beta-blockade as a cause of cardiac failure. Robson, R.H.; Vishwanath, M.C. // British Medical Journal (Clinical Research Edition);1/9/1982, Vol. 284 Issue 6309, p104 

    Presents a case report of a patient with pulmonary edema after nifedipine treatment in the absence of fixed outflow tract obstruction. Significance of nifedipine in patients with heart failure; Prevention of increased sympathetic activity through beta-blockade; Awareness on the potential...

  • Pleurisy and pulmonary granulomas after treatment with acebutolol. Wood, G.M.; Bolton, K.F.; Muers, M.F.; Losowsky, M.S. // British Medical Journal (Clinical Research Edition);10/2/1982, Vol. 285 Issue 6346, p936 

    Investigates the withdrawal effects of beta-blockers acebutolol used to control hypertension. Development of pleurisy and pulmonary granulomas after the treatment; Gradual disappearance of the symptoms during drug withdrawal; Adverse reaction of the drug.

  • Verdict goes against beta-blockers for hypertension in the elderly. O'Connor, Deborah L. // Patient Care;10/15/1998, Vol. 32 Issue 16, p23 

    Indicates that patients currently taking beta-blockers for hypertension are being exposed to the negative side effects, inconvenience and cost of these drugs. Suggestion that beta-blocker offers no primary cardioprotective benefit in elderly patients who has hypertension; Comments from doctor...

  • Does atenolol differ from other β-adrenergic blockers? Aursnes, Ivar; Osnes, Jan-Bjørn; Tvete, Ingunn Fride; Gåsemyr, Jørund; Natvig, Bent // BMC Clinical Pharmacology;2007, Vol. 7, p4 

    Background: A recent meta-analysis of drug effects in patients with hypertension claims that all β-adrenergic blockers are equally effective but less so than other antihypertensive drugs. Published comparisons of the β-adrenergic blocker atenolol and non-atenolol β-adrenergic blockers...

  • The Effect of β-Blockade on Leg Blood Flow in Hypertensive Patients with Intermittent Claudication. Boström, Per-Åke; Janzon, Lars; Ohlsson, Ola; Westergren, Anita // Angiology;Mar1986 Part 1, Vol. 37 Issue 3, p149 

    The present study was designed to assess the short-term effects of β-blocking antihypertensive treatment on leg blood flow in patients with peripheral artery disease. Seven patients with intermittent claudication were randomly allocated to treatment with atenolol 100 mg or pindolol 10 mg....

  • Nebivolol for Hypertension. Crawford, Michael H. // Clinical Cardiology Alert;Mar2009, Vol. 28 Issue 3, p20 

    Nebivolol is a new beta 1 selective blocker with vasodilatation properties via activation of the L-arginine/ nitric oxide pathway. Short-term studies, and a long-term, open-label study, have shown excellent efficacy and safety in stages 1-11 hypertension. Papademetriou presents the results of a...

  • When to review antihypertensives. Jackson, Graham; Ferro, Albert // Update;3/18/2004, Vol. 68 Issue 5, p243 

    A single antihypertensive drug is often not enough to control hypertension when treating to target 140/85 mmHg or less for patients with uncomplicated hypertension and 130/80 mmHg or less in patients with diabetes or other high-risk hypertensives and those with renal disease. However,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics